Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Official title: ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
129
Start Date
2026-03-16
Completion Date
2031-10-14
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Pumitamig
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Atezolizumab
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Locations (45)
Local Institution - 0070
Los Angeles, California, United States
Local Institution - 0107
Chicago, Illinois, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Local Institution - 0100
Great Neck, New York, United States
Local Institution - 0080
Portland, Oregon, United States
Local Institution - 0022
Nashville, Tennessee, United States
Local Institution - 0102
Nashville, Tennessee, United States
Local Institution - 0083
Seattle, Washington, United States
Local Institution - 0024
Camperdown, New South Wales, Australia
Local Institution - 0033
Westmead, New South Wales, Australia
Local Institution - 0040
Birtinya, Queensland, Australia
Local Institution - 0096
Melbourne, Australia
Local Institution - 0064
Santiago, Santiago Metropolitan, Chile
Local Institution - 0106
Santiago Region Metropolitana, Santiago Metropolitan, Chile
Local Institution - 0075
Guangzhou, Guangdong, China
Local Institution - 0086
Xi'an, Shaanxi, China
Local Institution - 0078
Shanghai, Shanghai Municipality, China
Local Institution - 0056
Pessac, Aquitaine, France
Local Institution - 0004
Grenoble, Isère, France
Local Institution - 0018
Saint Priest En Jarez, Pays de la Loire Region, France
Local Institution - 0003
Bobigny, France
Local Institution - 0031
Cologne, North Rhine-Westphalia, Germany
Local Institution - 0028
Kiel, Schleswig-Holstein, Germany
Local Institution - 0030
Frankfurt, Germany
Local Institution - 0109
Pisa, Tuscany, Italy
Local Institution - 0088
Milan, Italy
Local Institution - 0016
Pisa, Italy
Local Institution - 0046
Rozzano (MI), Italy
Local Institution - 0021
Wroclaw, Lower Silesian Voivodeship, Poland
Local Institution - 0105
Warsaw, Masovian Voivodeship, Poland
Local Institution - 0020
Gdansk, Poland
Local Institution - 0009
Singapore, Singapore
Local Institution - 0012
Singapore, Singapore
Local Institution - 0027
Seongnam-si, Gyeonggi-do, South Korea
Local Institution - 0013
Seoul, Seoul Teugbyeolsi, South Korea
Local Institution - 0011
Seoul, Seoul-teukbyeolsi, South Korea
Local Institution - 0014
Pamplona, Navarre, Spain
Local Institution - 0060
Madrid, Spain
Local Institution - 0032
Taichung, Taiwan
Local Institution - 0055
Tainan, Taiana, Taiwan
Local Institution - 0006
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Hammersmith Hospital
London, London, City of, United Kingdom
Local Institution - 0051
Glasgow, South Western Scotland, United Kingdom
Local Institution - 0053
Metropolitan Borough of Wirral, United Kingdom